Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2020 07:00 ET | Source: uniQure Inc.

uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology

~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Data show 91% reduction in reported bleeds requiring treatment, with 87% of patients reporting no...
December 07, 2020 16:05 ET | Source: uniQure Inc.

uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Long-term Clinical Benefit and...
December 07, 2020 12:01 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting

AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec....
December 05, 2020 15:01 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting

Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
November 30, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET...
November 17, 2020 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference

LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
November 04, 2020 10:46 ET | Source: uniQure Inc.

uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...